03A-1110221
Patent pending
A total synthesis of a series of potent cationic lipids is disclosed. The cationic lipids are designed for use in lipid nanoparticles (LNPs) to carry nucleic acids to mammalian cells for protein expression. Our results show that our new cationic lipid containing LNPs can efficiently deliver mRNA encoding the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Importantly, the mRNA delivery efficiency of our new cationic lipid containing LNPs is better than that other LNPs composed of commercially available cationic lipids (i.e., SM-102 or ALC-0315). We therefore propose the novel cationic lipid could be applied in LNPs for gene and drug delivery.
- a concrete and feasible synthesis method and a manufacturing method for preparing cationic lipid derivatives with improved stability
- Excellent mRNA delivery efficiency
- Vaccine
- Liposome Drug Delivery
- Gene Therapy
Wen-Shan Li, Han-Chung Wu, Jhih-Liang Huang, Ming-Hsiang Hong
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Potent cationic lipids, methods for preparation and applications of use thereof